AGEN1571 + Immunotherapy for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called AGEN1571 alone and with two other drugs in patients with advanced solid tumors. The goal is to find safe doses and see how well the drugs work. The drugs aim to either directly attack cancer cells or help the immune system fight them.
Eligibility Criteria
This trial is for adults with advanced solid tumors that have spread or are inoperable, and no standard treatments work or exist. They must be relatively healthy otherwise, with a life expectancy of at least 3 months and good organ function. Women who can have children and men with partners who can conceive must use effective birth control. People cannot join if they've had certain severe reactions to similar drugs, recent other treatments, active infections including HIV/HBV/HCV, significant heart issues, or uncontrolled high blood pressure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive AGEN1571 as monotherapy or in combination with balstilimab and/or botensilimab to determine the recommended phase 2 dose (RP2D)
Dose Expansion
Participants receive AGEN1571 at the RP2D for specific disease indications
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AGEN1571
- Balstilimab
- Botensilimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Agenus Inc.
Lead Sponsor